Jéssica Fernandes Ramos

Cytomegalovirus infection in transplant recipients

Cytomegalovirus infection is a frequent complication after transplantation. This infection occurs due to transmission from the transplanted organ, due to reactivation of latent infection, or after a primary infection in seronegative patients and can be defined as follows: latent infection, active infection, viral syndrome or invasive disease. This condition occurs mainly between 30 and 90 days after transplantation. In hematopoietic stem cell transplantation in particular, infection usually occurs within the first 30 days after transplantation and in the presence of graft-versus-host disease. The major risk factors are when the recipient is cytomegalovirus seronegative and the donor is seropositive as well as when lymphocyte-depleting antibodies are used. There are two methods for the diagnosis of cytomegalovirus infection: the pp65 antigenemia assay and polymerase chain reaction. Serology has no value for the diagnosis of active disease, whereas histology of the affected tissue and bronchoalveolar lavage analysis are useful in the diagnosis of invasive disease. Cytomegalovirus disease can be prevented by prophylaxis (the administration of antiviral drugs to all or to a subgroup of patients who are at higher risk of viral replication) or by preemptive therapy (the early diagnosis of viral replication before development of the disease and prescription of antiviral treatment to prevent the appearance of clinical disease). The drug used is intravenous or oral ganciclovir; oral valganciclovir; or, less frequently, valacyclovir. Prophylaxis should continue for 90 to 180 days. Treatment is always indicated in cytomegalovirus disease, and the gold-standard drug is intravenous ganciclovir. Treatment should be given for 2 to 3 weeks and should be continued for an additional 7 days after the first negative result for viremia.

Characterization of carbapenem-resistant Pseudomonas aeruginosa clinical isolates, carrying multiple genes coding for this antibiotic resistance

BackgroundCarbapenemase genes are one of the most frequent mechanisms reported in carbapenem-resistant P. aeruginosa; however, description of P. aeruginosa co-harbouring two or more carbapenemases is unusual.MethodsIn this study we evaluated the presence of carbapenemase genes and the clonality of P. aeruginosa isolates obtained from a hospital over a 12-year period. A total of 127 isolates of carbapenem-resistant P. aeruginosa recovered from 109 patients feces (four samples), rectal swab (three samples), nasal swab (one sample) and anal abscess (one sample), were evaluated. Minimum inhibitory concentrations of the following antibiotics imipenem, meropenem and polymyxin E were determined by broth microdilution. The molecular profile of isolates was evaluated by pulsed field gel electrophoresis (PFGE). PCR for the following carbapenemase genes blaIMP;blaSPM;blaVIM;blaSIM;blaNDM;blaKPC;blaGES and nucleotide sequencing to confirm the enzyme gene types were performed and compared with the database available on the Internet (BLAST-http://www.ncbi.nlm.nhi.gov/blast/).ResultsAll isolates were carbapenem-resistant, their MIC50 and MIC90 were respectively 64 μg/mL and 256 μg/mL to imipenem and 32 μg/mL and 256 μg/mL to meropenem, all isolates except one (MIC = 8 mg/L) were susceptible to polymyxin E. The most frequent carbapenemase genes identified were blaSPM identified in 41 isolates (32%), followed by 10 with blakpc and 5 with blaVIM (3.9%). All belonged to the class SPM-1 and VIM-2. In 2011, one isolate harbouring three carbapenemase genes (SPM-1, VIM-2 and KPC-2) that belonged to a new clone was identified in a hematopoietic stem cell transplanted patient. Then, 19 carbapenem-resistant P. aeruginosa were identified in an outbreak that occurred in the bone marrow transplant unit, all positive for SPM-1 gene, and 9 (47.3%) harbored both SPM-1 and KPC.ConclusionOur findings showed that PCR for KPC gene should be performed to evaluate carbapenem resistance in P. aeruginosa and that this agent can harbor more than one carbapenemase gene. Attention should be focused on the possible rapid spread of KPC in P. aeruginosa isolates and for the fact that P. aeruginosa may become a reservoir of this transmissible resistance mechanism.

Tuberculosis in Hematopoietic Stem Cell Transplant Recipients

Literature on tuberculosis (TB) occurring in recipients of Hematopoietic Stem Cell Transplant (HSCT) is scanty even in countries where TB is common. Most reports of TB in HSCT patients were from ASIA, in fact the TB incidence ranging from 0.0014 (USA) to 16% (Pakistan). There are few reports of TB diagnosis during the first two weeks after HSCT; most of cases described in the literature occurred after 90 days of HSCT, and the lung was the organ most involved. The mortality ranged from 0 to 50% and is higher in allogeneic HSCT than in autologous. There is no consensus regarding the screening with tuberculin skin test or QuantiFERON-TB gold, primary prophylaxis for latent TB, and whether the epidemiologic query should be emphasized in developing countries with high prevalence of TB.

Disseminated Fusarium infection in autologous stem cell transplant recipient

Disseminated infection by Fusarium is a rare, frequently lethal condition in severely immunocompromised patients, including bone marrow transplant recipients. However, autologous bone marrow transplant recipients are not expected to be at high risk to develop fusariosis. We report a rare case of lethal disseminated Fusarium infection in an autologous bone marrow transplant recipient during pre-engraftment phase.

MAIT cells are activated in acute Dengue virus infection and after in vitro Zika virus infection

Dengue virus (DENV) and Zika virus (ZIKV) are members of the Flaviviridae and are predominantly transmitted via mosquito bites. Both viruses are responsible for a growing number of infections in tropical and subtropical regions. DENV infection can cause lethargy with severe morbidity and dengue shock syndrome leading to death in some cases. ZIKV is now linked with Guillain-Barré syndrome and fetal malformations including microcephaly and developmental disorders (congenital Zika syndrome). The protective and pathogenic roles played by the immune response in these infections is unknown. Mucosal-associated invariant T (MAIT) cells are a population of innate T cells with potent anti-bacterial activity. MAIT cells have also been postulated to play a role in the immune response to viral infections. In this study, we evaluated MAIT cell frequency, phenotype, and function in samples from subjects with acute and convalescent DENV infection. We found that in acute DENV infection, MAIT cells had elevated co-expression of the activation markers CD38 and HLA-DR and had a poor IFNγ response following bacterial stimulation. Furthermore, we found that MAIT cells can produce IFNγ in response to in vitro infection with ZIKV. This MAIT cell response was independent of MR1, but dependent on IL-12 and IL-18. Our results suggest that MAIT cells may play an important role in the immune response to Flavivirus infections.

A case-series of Toxoplasmosis in hematopoietic stem cell transplantation: still a concern for endemic countries

Toxoplasmosis, among hematopoietic stem cell transplant (HSCT) recipients, was formerly considered as a rare disease with incidences reported varying from 0.8 to 8% depending on the seroprevalence of T. gondii in the studied population [1, 2]. However, recent data highlighted postHSCT toxoplasmosis as a potential life-threatening disease with a poor prognosis and reported mortality rates of up to 60% [3, 4]. Additionally, it has been shown that a considerable part of post-HSCT cases are diagnosed only after death, especially in those patients with disseminated disease [3, 4]. Post-HSCT toxoplasmosis is usually a result of a reactivation of a latent infection in seropositive patients instead of a primary infection [5]. Moreover, in this setting T. gondii may cause a severe invasive single-organ disease and the brain is the most frequently affected site, although disseminated disease has also been reported [6]. Most cases occur within the first 100 days after transplant and the highest-risk patients are seropositive allo-HSCT recipients who have received cord blood transplant, unrelated donor graft, T-cell depleted transplants, those who had high-grade graft-versus-host disease (GVHD), or are unable to take trimethoprin-sulphametoxazole (TMP/SMX) for Pneumocystis jirovecii prophylaxis (PJP) [2, 7]. In Brazil, as in Latin America and some regions in Central Europe the seroprevalence of toxoplasmosis is considered high with rates ranging from 50 to 80% over the country [8–10]. These rates are of interest, since the majority of our HSCT patients has a positive T. gondii serology pre-transplant, which puts them at risk for toxoplasmosis reactivation after transplant. Given that, we retrospectively analyzed all cases of toxoplasmosis among those patients who underwent HSCT at the Hospital das Clínicas of São Paulo University, Brazil, between January 2010 and April 2016. Medical charts and electronic records were reviewed to retrieve demographic information, underlying malignancy, the type and date of HSCT, GVHD characteristics, T. gondii serological status, conditioning regimen, use of corticosteroids, use of trimethoprinsulphametoxazole (TMP/SMX) prophylaxis, symptoms at presentation, time from HSCT to diagnose, toxoplasmosis definition, as well as type of treatment and outcome. Toxoplasma gondii serology screening using enzyme-linked immunosorbent assay (ELISA) and immunofluorescence antibody assay (IFA) was done for all patients before transplant. Polymerase chain reaction (PCR) using primers for 529 bp repeated element (RE) sequence was performed on blood, cerebrospinal fluid, bronchoalveolar lavage, and skin, to investigate toxoplasmosis disease considering the current definition [1]. A total of 771 patients underwent HSCT, of which 509 autologous (autoHSCT) and 262 allogeneic (allo-HSCT), between January 2010 and April 2016. Among allo-HSCT, 216 were from a related donor, 39 from an unrelated donor and 7 from a haploidentical donor. The underlying diseases were as follows: Acute Myeloid Leukemia (AML) (4); Hodgkin’s Lymphoma (1) and Acute Lymphoblastic Leukemia (ALL) (1). Patients characteristics are shown in Table 1. * Daniel P. Prestes danielprestes@hotmail.com

High mortality of bloodstream infection outbreak caused by carbapenem-resistant P. aeruginosa producing SPM-1 in a bone marrow transplant unit

PURPOSE Carbapenem resistance in P. aeruginosa is increasing worldwide. In Brazil, SPM-1 is the main P. aeruginosa carbapenemase identified. Little is known about the virulence factor in SPM-1 clones.Methodolgy. We describe a carbapenem-resistant P. aeruginosa bloodstream infection (CRPa-BSI) outbreak in a bone marrow transplant Unit (BMT). Twenty-nine CRPa-BSI cases were compared to 58 controls. Microbiological characteristics of isolates, such as sensitivity, carbapenemase gene PCR for P. aeruginosa, and PFGE are described, as well as the whole-genome sequence (WGS) of three strains.Results/Key findings. The cultures from environmental and healthcare workers were negative. Some isolates harboured KPC and SPM. The WGS showed that the 03 strains belonged to ST277, presented the same mutations in outer membrane protein, efflux pump, and virulence genes such as those involved in adhesion, biofilm, quorum-sensing and the type III secretion system, but differ regarding the carbapenemase profile. A predominant clone-producing SPM harbouring Tn 4371 was identified and showed cross-transmission; no common source was found. Overall mortality rate among cases was 79 %. The first multivariate analysis model showed that neutropenia (P=0.018), GVHD prophylaxis (P=0.016) and prior use of carbapenems (P=0.0089) were associated with CRPa-BSI. However, when MASCC>21 points and platelets were added in the final multivariate analysis, only prior use of carbapenems remained as an independent risk factor for CRPa-BSI (P=0.043). CONCLUSIONS The predominant clone belonging to ST277 showed high mortality. Carbapenem use was the only risk factor associated with CRPa-BSI. This finding is a wake-up call for the need to improve management in BMT units.

Carbapenem-resistant Pseudomonas aeruginosa carrying blaVIM-36 assigned as ST308: indicated non-virulence in G. mellonella model

OBJECTIVES Based on pulsed-field gel electrophoresis (PFGE) profile, whole-genome sequencing (WGS) of eight carbapenem-resistant Pseudomonas aeruginosa isolates from a bone marrow transplant unit in São Paulo, Brazil, was performed to investigate the presence of resistance and virulence genes as well as to determine the sequence type (ST) by multilocus sequence typing (MLST). METHODS The initial phenotypic susceptibility pattern of the isolates was determined by VITEK®2. Minimum inhibitory concentrations (MICs) were determined by the broth microdilution method for amikacin, meropenem and colistin. WGS was performed using an Illumina MiSeq system. A Galleria mellonella infection model was used to evaluate the virulence of the strains. RESULTS WGS demonstrated that mutations in genes encoding outer membrane proteins and efflux pumps in an isolate harbouring blaVIM-36 (ST308) differed from those in isolates harbouring blaSPM (ST277). The mexT gene harboured a mutation resulting in a frameshift in all isolates; in addition, the oprD gene of the blaVIM-36-carrying isolate had an insertion leading to a frameshift. Virulence genes did not differ between ST277 and ST308 strains. Moreover, only two isolates harbouring blaSPM showed virulence in the G. mellonella model, killing 100% of larvae after 18-24h. CONCLUSIONS P. aeruginosa carrying blaVIM-36 belonging to ST308 was identified for the first time in our hospital. Although the virulence gene profiles were similar in isolates carrying blaSPM and the isolate carrying blaVIM-36, only two isolates harbouring blaSPM showed virulence in the G. mellonella model.